trial

Deep Brain Stimulation in Treatment Resistant Schizophrenia

NCTId NCT02361554
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 15 (actual)
Sponsored by Johns Hopkins University
Primary completion 2026-02-28
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
15 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2023-03-01
Primary completion
2026-02-28
Eligibility
ALL · 22 Years · 65 Years

Interventions & indications

Drugs
Medtronic Percept with SensSight Deep Brain Stimulation System

Sponsors

Johns Hopkins UniversityLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Nicola CascellaPrincipal Investigator

Sites

1 total
Baltimore, United States

Facts & assertions

4 sourced
Enrollment
15
Phase
NA
Primary Completion Date
2026-02-28
Status
TERMINATED
relationships
The graph out of here
drug
Medtronic Percept with SensSight Deep Brain Stimulation System
drug
lead_sponsor
Johns Hopkins University
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia, Treatment-Resistant
indication
Treatment-resistant Schizophrenia
indication
investigator
Nicola Cascella
person